Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

NCT01465230 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
2
Enrollment
OTHER
Sponsor class

Stopped This study was unsuccessful in enrolling the target number of subjects during the funding period.

Conditions

Interventions

Sponsor

Yale University

Collaborators